ZZPZH(SH:600436) Zheng Quan Shi Bao·2025-06-22 17:54Core Viewpoint - The company aims to build itself into a world-class, top-tier pharmaceutical health industry group through continuous efforts in drug research and development, pharmaceutical commerce, daily chemical beauty, health food, and investment mergers and acquisitions, guided by the development philosophy of "Upholding Integrity and Innovation, Steady Progress for the Long Term" [2][11]. Company Strategy and Development - The 2024 annual shareholder meeting successfully completed voting on seven proposals, including the annual report, and highlighted the company's commitment to innovation and steady development [3][10]. - The company has prioritized "increasing technological innovation" in its future work plan for 2025, emphasizing the importance of innovation for sustainable development in the pharmaceutical industry [4][11]. Research and Development Achievements - The company has conducted 11 clinical studies and 23 pharmacological and toxicological studies for its core product, Pizhouhuang, and published 23 related research papers, showcasing significant results in the secondary development of traditional Chinese medicine [5][6]. - Pizhouhuang has been included in the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024)" by the Chinese Association of Traditional Chinese Medicine, indicating its recognition as a recommended drug for this condition [6]. Product Pipeline and Future Plans - The company has developed a pipeline of 18 projects covering traditional Chinese medicine and chemical drugs, targeting urgent clinical needs such as non-alcoholic fatty liver disease and chronic obstructive pulmonary disease, with plans to initiate 2 new drug projects and 3 to 5 new clinical studies in 2025 [7][11]. - The company is committed to increasing R&D investment to create "blockbuster" products in both traditional Chinese and chemical medicine, aiming to generate greater value for shareholders [7][11]. Shareholder Engagement - The shareholder meeting featured active participation from shareholders, with discussions on core product pricing, cash dividends, marketing strategies, and brand reputation, demonstrating transparency and engagement from the company's management [3][8][9]. - The company has implemented strategies to stabilize product pricing and enhance sales performance through optimized channels and partnerships with major online platforms [9]. Conclusion - The company is positioned as a leader in the traditional Chinese medicine industry, focusing on both core product enhancement and innovative drug development to explore new growth avenues while maintaining its heritage [11].